Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategies

Journal of Clinical Lipidology

Volumn 1, Issue 6, 2007, Pages 575-582

  Aronne, Louis J ^a,b   Brown, W Virgil ^c   Isoldi, Kathy Keenan ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b The Comprehensive Weight Control Program   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin; Bariatric surgery; Cardiovascular disease; Leptin; Metabolic syndrome; Obesity; Orlistat; Rimonabant; Risk factors; Sibutramine

Indexed keywords

ADIPONECTIN; AMFEBUTAMONE; ANGIOTENSINOGEN; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN; METFORMIN; PHENTERMINE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN; ZONISAMIDE;

ABDOMINAL OBESITY; ANXIETY; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; BLOATING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; FATIGUE; FLATULENCE; GASTRECTOMY; GASTRIC BANDING; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART PALPITATION; HIGH RISK POPULATION; HORMONE ACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INFLAMMATION; INSOMNIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORTALITY; NAUSEA; NONHUMAN; OBESITY; PARESTHESIA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PULSE RATE; REVIEW; RISK FACTOR; RISK REDUCTION; ROUX Y ANASTOMOSIS; SIDE EFFECT; TACHYCARDIA; TASTE AVERSION; UNITED STATES; WEIGHT REDUCTION; XEROSTOMIA;

EID: 36849029915     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.10.005     Document Type: Review

References (44)

1. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Finkelstein E.A., Fiebelkorn I.C., and Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying?. Health Aff (Millwood) Suppl Web Exclusives (2003) W3-219-W3-226
3. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
4. Bray G.A. Medical consequences of obesity. J Clin Endocrinol Metab 89 (2004) 2583-2589
5. Stein C.J., and Colditz G.A. The epidemic of obesity. J Clin Endocrinol Metab 89 (2004) 2522-2525
6. Puhl R., and Brownell K.D. Bias, discrimination, and obesity. Obes Res 9 (2001) 788-805
7. Jolliffe D. Extent of overweight among US children and adolescents from 1971 to 2000. Int J Obes Relat Metab Disord 28 (2004) 4-9
8. Daniels S.R. The consequences of childhood overweight and obesity. Future Child 16 (2006) 47-67
9. McMahan C.A., Gidding S.S., Malcom G.T., Tracy R.E., Strong J.P., and McGill Jr. H.C. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics 118 (2006) 1447-1455
10. Olshansky S.J., Passaro D.J., Hershow R.C., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352 (2005) 1138-1145
11. Robert Wood Johnson Foundation. Foundation Commits $500 Million to Reverse Childhood Obesity. http://www.rwjf.org/newsroom/feature.jsp?id=20920&typeid=151 Available at: Accessed May 25, 2007
12. Fontaine K.R., Redden D.T., Wang C., Westfall A.O., and Allison D.B. Years of life lost due to obesity. JAMA 289 (2003) 187-193
13. Koba S., Hirano T., Kondo T., et al. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. Am Heart J 144 (2002) 1026-1035
14. Wilson P.W., D'Agostino R.B., Sullivan L., Parise H., and Kannel W.B. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162 (2002) 1867-1872
15. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 91 (2003) 3A-6A
16. Trayhurn P., and Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92 (2004) 347-355
17. Dhurandhar N.V. Infectobesity: obesity of infectious origin. J Nutr 131 (2001) 2794S-2797S
18. Schmidt M.I., and Duncan B.B. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 41 (2003) 1120-1130
19. Korner J., and Aronne L.J. The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest 111 (2003) 565-570
20. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
21. Vendrell J., Broch M., Vilarrasa N., et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 12 (2004) 962-971
22. Lewis G.F., Carpentier A., Adeli K., and Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23 (2002) 201-229
23. Golay A., and Ybarra J. Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab 19 (2005) 649-663
24. Wassink A.M., Olijhoek J.K., and Visseren F.L. The metabolic syndrome: metabolic changes with vascular consequences. Eur J Clin Invest 37 (2007) 8-17
25. Eckel R.H., Kahn R., Robertson R.M., and Rizza R.A. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 113 (2006) 2943-2946
26. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
27. Lorenzo C., Williams K., Hunt K.J., and Haffner S.M. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30 (2007) 8-13
28. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
29. Misra A., and Vikram N.K. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition 19 (2003) 457-466
30. Despres J.P., Lemieux I., and Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 322 (2001) 716-720
31. National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Heart, Lung and Blood Institute; 2000. Available at: www.nhlbi.nih.gov/guidelines/obesity. Accessed May 10, 2007.
32. Hofbauer K.G., Nicholson J.R., and Boss O. The obesity epidemic: current and future pharmacological treatments. Annu Rev Pharmacol Toxicol 47 (2007) 565-592
33. Li Z., Maglione M., Tu W., et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142 (2005) 532-546
34. Korner J., and Aronne L.J. Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab 89 (2004) 2616-2621
35. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
36. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353 (2005) 2111-2120
37. DeMaria E.J. Bariatric surgery for morbid obesity. N Engl J Med 356 (2007) 2176-2183
38. Kyrou I., Valsamakis G., and Tsigos C. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann N Y Acad Sci 1083 (2006) 270-305
39. Engeli S., Böhnke J., Feldpausch M., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
40. Henness S., Robinson D.M., and Lyseng-Williamson K.A. Rimonabant. Drugs 66 (2006) 2109-2119 discussion 2120-2121
41. Pi-Sunyer F.X., Aronne L.J., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients, Rio-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
42. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
43. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
44. Scheen A.J., Finer N., Hollander P., Jensen M.D., and Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672